Ketorolac vs Oxycodone for Great Toe Arthrodesis

NCT ID: NCT05054868

Last Updated: 2023-07-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-14

Study Completion Date

2024-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study reviews if taking ketorolac, after a joint fusion procedure, can decrease the need for taking oxycodone (standard of care) for pain relief. The study also investigates if ketorolac affects bone healing after surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study reviews if taking ketorolac, after a joint fusion procedure, can decrease the need for taking oxycodone (standard of care) for pain relief. The study also investigates if ketorolac affects bone healing after surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthrodesis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 (Control group) - Oxycodone only

Subjects randomized to this group will receive oxycodone for postop pain management (standard of care).

Group Type ACTIVE_COMPARATOR

Oxycodone

Intervention Type DRUG

Subjects randomized to the control group will receive oxycodone for postop pain management (standard of care).

Group 2 (Treatment group) - Oxycodone and Ketorolac

Subjects randomized to this group will receive oxycodone and ketorolac for postop pain management.

Group Type EXPERIMENTAL

Oxycodone

Intervention Type DRUG

Subjects randomized to the control group will receive oxycodone for postop pain management (standard of care).

Ketorolac

Intervention Type DRUG

Subjects randomized to the treatment group will receive oxycodone and ketorolac for postop pain management.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxycodone

Subjects randomized to the control group will receive oxycodone for postop pain management (standard of care).

Intervention Type DRUG

Ketorolac

Subjects randomized to the treatment group will receive oxycodone and ketorolac for postop pain management.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 - 75 years.
* Women of childbearing potential must have a negative serum or urine pregnancy test results within 24 hours before the first dose of ketorolac.
* Primary elective great toe MTP arthrodesis (CPT 28750). Other forefoot procedures often performed in conjunction with toe fusion will be included (CPT codes 28308, 28285, 28270).

Exclusion Criteria

* Chronic pain syndrome, CRPS or fibromyalgia
* Revision procedures
* Use of allograft bone at the fusion site
* Tobacco use
* Diabetes
* Narcotic abuse or IV drug abuse
* Any CPT codes involving the midfoot, hindfoot, and/or ankle
* Unable to take NSAIDs secondary to medical comorbidities such as kidney disease (impaired renal function with CrCl ≤ 50 ml/min) or gastric ulcers
* Weight \< 50 kg
* Does not speak or read English
* If pregnant or planning to become pregnant or breastfeeding
* Non-independent dweller (prisoner)
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medstar Health Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Amy Loveland

Baltimore, Maryland, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Amy Loveland

Role: CONTACT

3015602937

Crisanto Macaraeg

Role: CONTACT

410-261-8218

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Amy Loveland

Role: primary

301-560-2937

Crisanto Macaraeg

Role: backup

4102618218

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STUDY00001123

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pain Control After Lumbar Spine Fusion
NCT06484192 ENROLLING_BY_INVITATION PHASE4
Acute Pain and Inflammation After Surgery
NCT00774540 COMPLETED PHASE4